Want to see AU:MAP full AI Analyst Report?

Microba Life Sciences Limited (MAP) Price & Analysis

4 Followers

MAP Stock Chart & Stats

AU$0.08

>-AU$0.01(-1.89%)

At close: Jan 09 4:00 PM EST

AU$0.08

>-AU$0.01(-1.89%)

Day’s Range― - ―

52-Week RangeAU$0.04 - AU$0.11

Previous CloseN/A

Volume476.46K

Average Volume (3M)469.77K

Market Cap

AU$25.21M

Enterprise ValueAU$12.08M

Total Cash (Recent Filing)AU$11.27M

Total Debt (Recent Filing)AU$3.31M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding700,307,500

10 Day Avg. Volume548,444

30 Day Avg. Volume469,774

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)1.17

Price to Sales (P/S)2.43

P/FCF Ratio-2.56

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.14

Price Target Upside68.75% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.02

Revenue Forecast (FY)AU$24.70M

Bulls Say, Bears Say

Bulls Say

Low LeverageA debt-to-equity of 0.10 gives Microba substantial balance sheet resilience versus peers. Low leverage reduces refinancing and interest burden, allowing management to fund R&D, absorb short-term losses, and pursue partnership deals without immediate capital markets pressure.

Positive Free Cash Flow GrowthFree cash flow growth and FCF exceeding net income indicate the company can convert operations into cash despite accounting losses. This durable cash generation trend supports ongoing operations, selective investment, and preserves optionality for strategic collaborations or non-dilutive funding.

Platform-based, Diversified Revenue ModelMicroba's platform serves clinical/consumer testing, B2B research and pharma collaborations, providing multiple revenue pillars. A platform business can scale with volume, enable recurring services, and create sticky relationships with researchers and partners, strengthening long-term market position.

Bears Say

Declining RevenueA roughly 24% revenue decline materially reduces operating scale and weakens the economics of the platform. Sustained top-line contraction undermines fixed cost absorption, constrains reinvestment capacity, and makes it harder to demonstrate traction to long-term collaborators and customers.

Persistent Losses And Weak ProfitabilityConsistent negative margins show Microba has not yet reached profitable unit economics. Over months this pressures retained earnings, limits internally funded growth, and risks dilutive capital raises or curtailed investment in product and commercialization without a clear path to margin improvement.

Negative Operating Cash FlowNegative operating cash flow signals ongoing cash burn from core activities. Without reversal or external funding, this hampers the company's ability to scale lab capacity, support long-term studies or sustain partnership commitments, increasing reliance on financing and strategic agreements.

Microba Life Sciences Limited News

SA Microba Holdings exits substantial holder status in Microba Life Sciences

Microba Life Sciences Limited ( ($AU:MAP) ) has issued an announcement. SA Microba Holdings Pty Ltd has ceased...

9d ago

MAP

Microba calls July general meeting to back capital raising and fund growth

Microba Life Sciences Limited ( ($AU:MAP) ) has provided an update. Microba Life Sciences has called a general...

9d ago

MAP

Microba Details $6 Million Capital Raising and Issues Cleansing Notice

Microba Life Sciences Limited ( ($AU:MAP) ) has shared an announcement. Microba Life Sciences has confirmed key details...

13d ago

MAP

Microba Life Sciences launches conditional SPP and options offer to raise up to $1m

Microba Life Sciences Limited ( ($AU:MAP) ) just unveiled an update. Microba Life Sciences Limited has launched a...

13d ago

MAP

Microba seeks ASX quotation for 91 million new shares

Microba Life Sciences Limited ( ($AU:MAP) ) just unveiled an update. Microba Life Sciences Limited has applied for...

14d ago

MAP

Microba halts ASX trading ahead of capital raise and breakeven update

Microba Life Sciences Limited ( ($AU:MAP) ) has shared an update. Microba Life Sciences Limited, a microbiome-focused health...

29d ago

MAP

Microba Life Sciences Options Lapse, Trimming Potential Dilution

Microba Life Sciences Limited ( ($AU:MAP) ) has issued an update. Microba Life Sciences Limited has updated the...

2M ago

MAP

Microba Launches Q3 FY26 Investor Webinar and Expands Interactive Investor Hub

Microba Life Sciences Limited ( ($AU:MAP) ) has provided an announcement. Microba Life Sciences Limited has released its...

2M ago

MAP

Microba Rides Testing Surge, Eyes Deal and New Diagnostic Launch

An update from Microba Life Sciences Limited ( ($AU:MAP) ) is now available. Microba Life Sciences reported strong...

2M ago

MAP

Microba boosts core microbiome testing as it exits legacy products and targets FY26 break-even

An update from Microba Life Sciences Limited ( ($AU:MAP) ) is now available. Microba Life Sciences reported strong...

4M ago

MAP

MAP FAQ

What was Microba Life Sciences Limited’s price range in the past 12 months?

Microba Life Sciences Limited lowest share price was AU$0.04 and its highest was AU$0.10 in the past 12 months.

What is Microba Life Sciences Limited’s market cap?

Microba Life Sciences Limited’s market cap is AU$25.21M.

When is Microba Life Sciences Limited’s upcoming earnings report date?

Microba Life Sciences Limited’s upcoming earnings report date is Sep 01, 2026 which is in 61 days.

How were Microba Life Sciences Limited’s earnings last quarter?

Microba Life Sciences Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.018 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.008.

Is Microba Life Sciences Limited overvalued?

According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Microba Life Sciences Limited pay dividends?

Microba Life Sciences Limited does not currently pay dividends.

What is Microba Life Sciences Limited’s EPS estimate?

Microba Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Microba Life Sciences Limited have?

Microba Life Sciences Limited has 700,307,500 shares outstanding.

What happened to Microba Life Sciences Limited’s price movement after its last earnings report?

Microba Life Sciences Limited reported an EPS of -AU$0.018 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 1.176%.

Which hedge fund is a major shareholder of Microba Life Sciences Limited?

Currently, no hedge funds are holding shares in AU:MAP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Microba Life Sciences Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.04%

Trailing 12-Months

Asset Growth

-14.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Microba Life Sciences Limited

Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.

Microba Life Sciences Limited (MAP) Earnings & Revenues

Historic Earnings Reports

MAP Stock 12 Month Forecast

Average Price Target

AU$0.14

▲(68.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.068,0.07430769230769231,0.08061538461538462,0.08692307692307692,0.09323076923076923,0.09953846153846155,0.10584615384615384,0.11215384615384616,0.11846153846153845,0.12476923076923077,0.1310769230769231,0.13738461538461538,0.14369230769230767,{"y":0.15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.068,0.07315384615384615,0.07830769230769231,0.08346153846153846,0.08861538461538462,0.09376923076923077,0.09892307692307692,0.10407692307692308,0.10923076923076924,0.11438461538461539,0.11953846153846154,0.1246923076923077,0.12984615384615383,{"y":0.135,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.068,0.07200000000000001,0.076,0.08,0.084,0.088,0.092,0.096,0.1,0.104,0.108,0.11199999999999999,0.11599999999999999,{"y":0.12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.145,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.085,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.089,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.094,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.082,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.079,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.074,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.076,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.087,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.083,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.069,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.076,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.068,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >